Postmarketing Surveillance Study of Atrovent® Inhalation Solution in Chronic Obstructive Pulmonary Disease
NCT02238197 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 477
Last updated 2014-09-12
Summary
To obtain further information on the tolerability and efficacy of Atrovent® 500µg/2ml inhalation solution in the treatment of Chronic Obstructive Pulmonary Disease under conditions of daily practice
Conditions
- Pulmonary Disease, Chronic Obstructive
Interventions
- DRUG
-
Atrovent® Inhalation Solution
Sponsors & Collaborators
- lead INDUSTRY
Eligibility
- Min Age
- 13 Years
- Max Age
- 89 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2001-02-28
- Primary Completion
- 2001-10-31
More Related Trials
-
Postmarketing Surveillance of Atrovent® in Chronic Obstructive Pulmonary Disease
NCT02238158 ·Status: COMPLETED
-
Postmarketing Surveillance Study of Anticholinergics - Prescribing Pattern and Therapeutic Long Term Value in Patients Suffering From Moderate or Severe Chronic Obstructive Pulmonary Disease (COPD)
NCT02238184 ·Status: COMPLETED
-
Post-marketing Surveillance of Ventilat® Metered Dose Inhaler in Chronic Obstructive Bronchitis
NCT02233920 ·Status: COMPLETED
-
Post-marketing Surveillance of Ventilat® in Long-term Therapy in Chronic Obstructive Pulmonary Disease
NCT02233907 ·Status: COMPLETED
-
Postmarketing Surveillance Study of Berodual® Metered-dose Inhaler in Chronic Obstructive Respiratory Tract Disease
NCT02232594 ·Status: COMPLETED
-
Trial to Determine the Comparability of Ipratropium Bromide Hydrofluoroalkane (HFA)-134a Inhalation Aerosol to ATROVENT® Chlorofluorocarbon (CFC) Inhalation Aerosol, in Patients With Chronic Obstructive Pulmonary Disease (COPD)
NCT02236169 ·Status: COMPLETED ·Phase: PHASE2
-
Postmarketing Surveillance Study of Berodual® Metered-dose Inhaler in Chronic Obstructive Airways Disease
NCT02231424 ·Status: COMPLETED
-
PT001 MDI Versus Atrovent Study in Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)
NCT01350128 ·Status: COMPLETED ·Phase: PHASE2
-
Study of the Comparability of Ipratropium Bromide Hydrofluoroalkane (HFA)-134a Inhalation Aerosol to the Market Standard, Atrovent® Chlorofluorocarbon (CFC) Inhalation Aerosol, in Patients With Chronic Obstructive Pulmonary Disease
NCT02260011 ·Status: COMPLETED ·Phase: PHASE2
-
Postmarketing Surveillance Study of Berotec® N 100 µg Metered-dose Inhaler in Chronic Obstructive Respiratory Tract Disease
NCT02244216 ·Status: COMPLETED
-
Efficacy and Safety of Tiotropium and Atrovent in Subjects With Chronic Obstructive Pulmonary Disease (COPD)
NCT02172469 ·Status: COMPLETED ·Phase: PHASE3
-
Actuation Indicator Trial in Patients With COPD
NCT00928746 ·Status: COMPLETED ·Phase: PHASE3
-
Efficacy and Safety of Tiotropium Inhalation Capsules and Atrovent MDI in Patients With Chronic Obstructive Pulmonary Disease (COPD)
NCT00274092 ·Status: COMPLETED ·Phase: PHASE3
-
Clinical Pharmacology Study to Evaluate the Total Systemic Exposure and the Lung Availability of CHF 5993 in Healthy Volunteers
NCT02743013 ·Status: COMPLETED ·Phase: PHASE1
-
Clinical Pharmacology Study to Evaluate the Total Systemic Exposure and Lung Bioavailability of CHF 5993 pMDI Combination in Healthy Volunteers
NCT02359292 ·Status: COMPLETED ·Phase: PHASE1
-
Post-marketing Surveillance of Berodual® Metered-dose Inhaler in the Treatment of Chronic Obstructive Respiratory Tract Disease
NCT02231437 ·Status: COMPLETED
-
Functional Respiratory Imaging Study (FRI)
NCT03268226 ·Status: COMPLETED ·Phase: PHASE3
-
Efficacy of Fixed Combination of Beclomethasone Dipropionate (BDP) + Formoterol Fumarate (FF) + Glycopyrronium Bromide (GB) (CHF 5993)Administered Via Dry Powder Inhaler (DPI) in Chronic Obstructive Pulmonary Disease (COPD)
NCT03590379 ·Status: COMPLETED ·Phase: PHASE2
-
Safety and Efficacy of Two Different Doses of Ipratropium Bromide Versus ATROVENT® Inhalation Aerosol in Adults With Chronic Obstructive Pulmonary Disease
NCT02177344 ·Status: COMPLETED ·Phase: PHASE3
-
DETECT-Register DocumEnTation and Evaluation of a COPD Combination Therapy
NCT02552160 ·Status: COMPLETED
-
Efficacy and Tolerability Study in Severe Chronic Obstructive Pulmonary Disease (COPD) Patients
NCT01415518 ·Status: COMPLETED ·Phase: PHASE4
-
Postmarketing Surveillance Study to Assess Handling and Patient Satisfaction on Berodual® Respimat® Solution for Inhalation in Patients With Chronic Obstructive Pulmonary Disease
NCT02231320 ·Status: COMPLETED
-
Combivent Respimat 1-year Safety Study in Patients With Chronic Obstructive Pulmonary Disease
NCT01019694 ·Status: COMPLETED ·Phase: PHASE3
-
A Study Characterizing Pharmacodynamic Profiles in Subjects With Chronic Obstructive Pulmonary Disease
NCT01113593 ·Status: COMPLETED ·Phase: PHASE2
-
A 6-week Dose Ranging Study of CHF 5259 pMDI in Subjects With Chronic Obstructive Pulmonary Disease
NCT03084796 ·Status: COMPLETED ·Phase: PHASE2